PathogenDx, Zef Scientific partner to offer microbial testing platform
Category: #health  By Pankaj Singh  Date: 2019-07-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

PathogenDx, Zef Scientific partner to offer microbial testing platform

The propriety technology offered by PathogenDx will set a new standard in Canada for testing bacteria

PathogenDx, Inc., a technology company that provides testing solutions to food, agriculture and botanical testing markets, recently announced it has entered into a strategic partnership with Zef Scientific for sales and distribution of microbial testing in Canada.

Under the agreement, both companies aim to grow their accounts nationally, while the partnership has already wrapped up its first account with a testing lab in Canada.

Reportedly, Zef Scientific works with a number of major equipment manufacturers like Shimadzu and take pride in being able to provide laboratories with multi-vendor solutions. The company’s scope ranges from pharmaceutical laboratories to modern cannabis facilities for testing.

Kevork Kalaydjian, Sales Director at Zef Scientific said that the company’s new partnership with PathogenDx will expand their portfolio to include fungal and bacterial testing through PathogenDx’s offered technology, that is unique and DNA-based.

ZefSci is looking forward to offering new line of instrumentation to the Cannabis market in Canada. The proprietary technology offered by PathogenDx will help set a new standard for testing bacteria in the country, a solution that would make sense, Kalaydjian added.

Milan Patel, Co-Founder and CEO of PathogenDx said in an announcement that the partnership and agreement between PathogenDx and Zef Scientific will offer Canadian Cannabis market new access to ultra-fast microbial testing turnaround times. Owing to major regulatory mandates in order to protect recreational consumer safety and patients, the Canadian market has faced certain supply challenges.

The partnership will offer Canadian retailers, regulators, distributors and growers a chance to shorten approval times and testing with greater precision, while also securing safer and better products to market faster for consumers and patients in Canada, Patel mentioned.

Seemingly, molecular technologies are increasingly being adopted by Cannabis testing labs in order to meet the testing mandates for pathogen and avoid relying on culture based methods. Cannabis was legalized for recreational and medicinal use the previous year.

Source Credit- https://www.biospace.com/article/releases/pathogendx-and-zef-scientific-announce-a-strategic-sales-and-service-distribution-partnership-for-microbial-testing-in-canada/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...